CD19 and neoplasm: However, when tumor cells expressed only a single antigen (i.e., CD19 or CD79), bispecific CAR-T cells showed compromised efficacy compared to monospecific CAR-T cells, due to less efficient antigen binding and reduced downstream signaling.